Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Effect of SARS-CoV-2 variant emergence on efficacy of neutralizing antibodies and vaccines

A review article focuses on the efficacy of neutralizing antibodies and vaccines against the SARS-CoV-2 variants.

9 Dec 2021

Immune responses against SARS-CoV-2 Delta variant after BNT162b2 vaccination in people living with HIV

Researchers from Sorbonne Universite have been investigating the effect of the BNT162b2 mRNA vaccine on HIV-positive individuals.

9 Dec 2021

Immunogenicity and safety of COVID-19 subunit vaccine Nanocovax in animal models

Researchers have developed Nanocovax, a COVID-19 subunit vaccine based on recombinant protein technology to produce the extracellular (soluble) portion of the S protein of SARS-CoV-2.

9 Dec 2021

SARS-CoV-2 variants are evolving new ways to evade antibodies and vaccines

Continued replication of severe acute respiratory syndrome-associated coronavirus 2 (SARS-CoV-2) under selective pressure from natural and vaccine-induced immunity has led to the emergence of variants of concern (VOCs) with increased transmissibility or virulence.

8 Dec 2021

Neutralization antibodies elevated in nursing home residents after COVID-19 mRNA boosters

Researchers from the United States, in their recent study published on the preprint server medRxiv*, have evaluated the humoral responses to third vaccine dose in nursing home residents and healthcare workers (HCW) and found that that second booster (or third vaccine dose) significantly increased anti-spike, anti-receptor binding domain (RBD), and neutralization titers in almost all nursing home residents and HCW to considerably higher levels than what was attained after the completion of the initial two-dose vaccine series.

8 Dec 2021

Thousands of the UK’s most vulnerable people to receive cutting-edge COVID-19 treatments at home

Thousands of the UK's most vulnerable people will be among the first in the world to access life-saving, cutting-edge antiviral and antibody treatments from today, the government has announced.

8 Dec 2021

New hormone may play a key role in the development of type 1 and type 2 diabetes

A newly discovered hormone named fabkin helps regulate metabolism and may play an important role in the development of both type 1 and type 2 diabetes, according to research led by the Sabri Ülker Center for Metabolic Research at Harvard T.H. Chan School of Public Health.

8 Dec 2021

Study shows SARS-CoV-2 transmission in Ireland before first official COVID-19 report

New study findings showed evidence of SARS-CoV-2 dissemination in Ireland prior to the identification of the first official COVID-19 case.

8 Dec 2021

AlphaFold AI predicts SARS-CoV-2 omicron variant might not evade antibody neutralization

In a new study, scientists have computationally predicted the structure of the Omicron spike RBD from available sequences and explored the dynamics of antigen-antibody interactions.

8 Dec 2021

Characterization of the baseline SARS-CoV-2 S-reactive B cell repertoire

Researchers from the University Of Amsterdam have identified several oddities in unvaccinated individuals' antibody response to the spike protein.

8 Dec 2021

SARS-CoV-2 antibody profiles in vaccinated and convalescent macaques compared to humans

New findings suggest that Macaque monkeys may not be the ideal model when testing for SARS-CoV-2.

8 Dec 2021

Canopy Biosciences launches the first of a series of targeted assay kits for ChipCytometry

Canopy Biosciences, a Bruker Company, today announced the launch of a first in a series of assay kits for ChipCytometry, a quantitative, high dynamic range and high-resolution multiplexing technology for spatial proteomics.

From Bruker Nano Surfaces and Metrology 8 Dec 2021

Combination of vaccination and natural infection offers utmost protection against COVID variants

A combination of vaccination and naturally acquired infection appears to boost the production of maximally potent antibodies against the COVID-19 virus, new UCLA research finds.

8 Dec 2021

Rapid antigen detection test for SARS-CoV-2 proves more effective than expected, large study reports

In what is believed to be the largest prospective study of its kind to date - involving some 6,000 patients seen at the Baltimore Convention Center Field Hospital (BCCFH) during a 10-day period around the beginning of 2021 - researchers at Johns Hopkins Medicine, the University of Maryland Medical Center, the University of Maryland School of Medicine and four other collaborators report that a rapid antigen detection test for SARS-CoV-2, the virus that causes COVID-19, proved more effective than expected when compared with virus detection rates using the established standard test, the polymerase chain reaction (PCR) assay.

8 Dec 2021

Antibody News and Research

Further Reading

Effect of SARS-CoV-2 variant emergence on efficacy of neutralizing antibodies and vaccines

Immune responses against SARS-CoV-2 Delta variant after BNT162b2 vaccination in people living with HIV

Immunogenicity and safety of COVID-19 subunit vaccine Nanocovax in animal models

SARS-CoV-2 variants are evolving new ways to evade antibodies and vaccines

Neutralization antibodies elevated in nursing home residents after COVID-19 mRNA boosters

Thousands of the UK’s most vulnerable people to receive cutting-edge COVID-19 treatments at home

New hormone may play a key role in the development of type 1 and type 2 diabetes

Study shows SARS-CoV-2 transmission in Ireland before first official COVID-19 report

AlphaFold AI predicts SARS-CoV-2 omicron variant might not evade antibody neutralization

Characterization of the baseline SARS-CoV-2 S-reactive B cell repertoire

SARS-CoV-2 antibody profiles in vaccinated and convalescent macaques compared to humans

Canopy Biosciences launches the first of a series of targeted assay kits for ChipCytometry

Combination of vaccination and natural infection offers utmost protection against COVID variants

Rapid antigen detection test for SARS-CoV-2 proves more effective than expected, large study reports

SARS-CoV-2 re-infection from new variant after natural infection

SARS-CoV-2 Delta variant changes receptor binding domain conformation to escape host antibodies

Antibody response to COVID-19 vaccine may be affected by the body’s circadian rhythms

New approach to enhance the therapeutic efficacy of liver cancer immunotherapy

Combination of prior infection and vaccination produces a more potent defense against SARS-CoV-2

SARS-CoV-2 surveillance in urban wildlife from Ontario and Québec

Immunology eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo